GlassScriptPhysician profile
Karimeldin Awad
NPI 1245718923
$3,657.70
in general payments reported to CMS, 2019-2025
18 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.06 · 2022: $146 · 2023: $1,335 · 2024: $1,144 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.07 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $610.07 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.33 | 2021-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $419.88 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $314.65 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $190.56 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $171.59 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $147.32 | 2022-2025 | |
| Dynavax Technologies Corporation | $99.45 | 2023-2025 | Heplisav-B |
| Dexcom, INC. | $94.59 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $78.80 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.71 | 2024-2025 | |
| Abbvie INC. | $48.19 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $23.78 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $23.26 | 2024 | Keveyis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.63 | 2022 | |
| Abbott Laboratories | $17.48 | 2025 | Freestyle Libre 3 |
| Si-Bone, INC. | $17.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karimeldin Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.